<DOC>
	<DOCNO>NCT02133404</DOCNO>
	<brief_summary>To examine efficacy safety 12-week administration ASP7991 secondary hyperparathyroidism patient undergoing hemodialysis</brief_summary>
	<brief_title>A Study Evaluate Effect ASP7991 Secondary Hyperparathyroidism Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>This study multicenter , double-blind , randomize , Cinacalcet hydrochloride-controlled , parallel-group , dose-ascending study . Subjects judge eligible registered randomize either ASP7991 group ( receive ASP7991 cinacalcet-placebo ) Cinacalcet group ( receive cinacalcet ASP7991-placebo ) , receive 12-week ( 84 day ) administration study drug first dialysis day week ( treatment period ) , double-blind manner . The dose study drug increase every 3 week dose-ascending manner . Follow-up assessment perform start first dialysis week , 1 week ( 7 day ) completion treatment period .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Patients stable chronic maintenance dialysis receive hemodialysis therapy 3 times/week since 12week ( 84 day ) administration also schedule undergo regimen 3 times/week hemodialysis study period Patients secondary hyperparathyroidism Patients whose serum iPTH concentration &gt; 240 pg/mL correct serum Ca ≥ 9.0 mg/dL Patients change follow item ≥4week ( 28 day ) . Dosage regimen , include new administration , active vitamin D , calcitonin preparation , phosphate binder , medication phosphate absorption ( include food ) Ca concentration dialysate , membrane area dialyzer , dialysis time week Patients underwent parathyroid intervention , parathyroidectomy ( PTx ) percutaneous ethanol injection therapy ( PEIT ) , within 24 week ( 168 day ) prior administration Patients primary hyperparathyroidism Patients receive bisphosphonate , estrogen preparation , parathyroid hormone within 4 week ( 28 day ) Patients uncontrolled hypertension ( systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 120 mmHg observe &gt; 2/3 confirmable measurement Patients complicate severe heart disorder [ congestive cardiac failure ( NYHA classification III high ) , wide range old myocardial infarction ] , history hospitalization cerebrovascular disease heart disorder within 12 week ( 84 day ) administration study drug Patients hepatic function abnormal ( ALT AST &gt; 2× ULN , total bilirubin ( Tbil ) &gt; 1.5 × ULN . ) Patients history malignant tumor patient 's condition complicate malignant tumor . ( However , enrollment acceptable tumor relapse 5 year longer . ) Patients history serious drug allergy include anaphylactic shock Patients history drug allergy Cinacalcet hydrochloride Female patient potentially childbearing lactating , patient comply instructed contraceptive measure Patients currently involve trial investigational drug medical device , clinical trial postmarketing study drug within 12 week ( 84 day ) study Patients receive ASP7991 past Patients judge ineligible participate study investigator / subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>secondary hyperparathyroidism ( SHPT )</keyword>
	<keyword>Chronic kidney disease ( CKD )</keyword>
	<keyword>Mineral bone disease ( MBD )</keyword>
</DOC>